In a market believed to approach 5 million people in the leading pharma markets, the market for rheumatic anti-inflammatory drugs is both profitable and set to increase due to new launches. The annual revenue to Q3 2006, from the main prescription anti-inflammatory drugs worldwide, including non steroidal anti-inflammatories (NSAIDs), anti-rheumatic corticosteroid combinations and specific anti-rheumatics was in the order of $16bn worldwide. This market cannot be ignored. A life-long disease with no cure, the disease has been targeted greatly by pharma companies with the launch of novel targeted biologic therapies. However this has meant that the market for severe RA has become crowded – but is it saturated?
Historically management of RA has relied on symptomatic treatment with a variety of anti-inflammatories, toxic immunosuppressants and corticosteroids. None of these treatments, however, had the ability to prevent underlying disease progression. The advent of a series of new biological monoclonal antibodies to treat RA has changed this situation dramatically. There is now a real possibility of actually modifying the progression of chronic disease, decreasing disability levels and enabling more normal lifestyles for RA patients.
These new monoclonal antibodies specifically target the early pathways of inflammation preventing damage and abrogating the onset of the vicious cycle of inflammation and tissue destruction. The first new biological drugs for RA are already on the market and have met with outstanding clinical success. There are now several important regulatory issues concerning the older biological drugs as patents are expiring and the biosimilar race by generic companies gets underway. There is also a strong pipeline of new drugs in development which could make exciting and important breakthroughs.
Questions however remain, that this new report will answer for you, such as: Will the current monoclonal blockbuster used to treat RA continue to grow? How dark is the future for coxibs and as a drug class are they doomed? What are the hottest research drugs in the pipeline? Will the manufacture and marketing of biosimilars overcome regulatory hurdles?
The main treatment categories discussed in the report include :
nonsteroidal anti-inflammatories (NSAIDs, COX inhibitors known as coxibs)
corticosteroids
viscosupplements (for joints) – Synvisc and Suvenyl
new biologicals (anti-TNF), Kineret ( anti IL-1Ra )
MabThera/Rituxan (anti-CD 20), Orencia (anti-IL-2 and IL-4)
With new expensive biological drugs targeted at the US, Europe and Japan, generating revenues of $9450m in the last 12 months, visiongain believe that the growth of the disease within developing nations will see cheaper alternatives increase revenue also.
With global market analysis and forecast right through to 2012, the report tackles a SWOT breakdown affecting the use of NSAIDs and biologicals. Targeted immunology relating to RA and sets out the targets for future research. This is taken up in the pipelines chapter which deals with the pipeline. These two chapters have been designed to allow the reader to get a good summary of what is opening up in the future treatment for RA. Visiongain sees a continuing shift towards biological treatment of RA and the treatment options are expanding. Biologicals provide greater opportunity to modulate disease progression and alleviate the chronic cycle of inflammation and pathology. Leading biological companies have strong pipelines and time will determine the future potential of the next generation of anti-inflammatory drugs. In the meantime, the use of traditional mainstay drugs will continue until newer agents have a proven record of safety and efficacy. The early signs with the novel therapies look very promising.
- Exclusive information of market shares and revenues till 2012 for all of the major drugs have been forecast -
For more information kindly visit
http://www.bharatbook.com/
